Headlines about DURECT (NASDAQ:DRRX) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. DURECT earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 45.9658271870473 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern’s analysis:
- What Makes New York Mtge Trust (NYMT) and Durect Corporation (DRRX) Different? – Post Registrar (postregistrar.com)
- Investors watching Analysts Rating of DURECT Corporation (DRRX) – Wall Street Morning (wallstreetmorning.com)
- Notable Stocks on the Move: DURECT Corporation, (NASDAQ: DRRX), CBS Corporation, (NYSE: CBS) – StocksNewsPro (press release) (stocksnewspro.com)
- DURECT Corporation, (NASDAQ: DRRX) – Is the Stock Safe to Invest? – Stock Watch (stocksnewstimes.com)
- Is DURECT Corporation (NASDAQ:DRRX) Undervalued? (finance.yahoo.com)
Shares of DURECT (NASDAQ DRRX) opened at $1.87 on Wednesday. The stock has a market capitalization of $286.74, a P/E ratio of -47.25 and a beta of 1.71. DURECT has a 1 year low of $0.74 and a 1 year high of $2.17. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.87 and a quick ratio of 2.67.
A number of brokerages recently issued reports on DRRX. BidaskClub raised DURECT from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine raised DURECT from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Finally, HC Wainwright raised DURECT from a “neutral” rating to a “buy” rating and lifted their target price for the company from $1.50 to $3.50 in a research report on Tuesday, March 6th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $2.83.
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.